LungLife AI, Inc. (LLAI.L) Research

LungLife AI, Inc. is a clinical diagnostics enterprise focused on creating AI-powered solutions for detecting lung cancer. The company is actively developing LungLB, an advanced blood-based test that harnesses artificial intelligence and machine learning. LungLB is designed to precisely identify and quantify circulating tumor cells (CTCs), ultimately aiming to minimize manual intervention and elevate diagnostic performance. The organization, which was previously known as Cynvenio Biosystems, Inc., adopted the LungLife AI, Inc. moniker in May of 2019. Its operations are based in Thousand Oaks, California.

Market snapshot

Symbol
LLAI.L
Price
$4.15
Day change
-2.35%
Market cap
$14.9M
P/E ratio
-2.76x
52-week range
0.8-21.7
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • Cel AI PLC (CLAI.L)
  • DeepVerge plc (DVRG.L)
  • Hellenic Dynamics Plc (HELD.L)
  • Kanabo Group Plc (KNB.L)
  • LungLife AI, Inc. (LLA.L)
  • Oxford Cannabinoid Technologies Holdings Plc (OCTP.L)
  • Oncimmune Holdings plc (ONC.L)
  • Ovoca Bio plc (OVB.L)

Open LungLife AI, Inc. (LLAI.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.